TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28143536

Group type: EXPERIMENTAL
Intervention: High resilience women
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Low resilience women
Number of subjects: 126

Group type: COMPARATOR
Intervention: Spouses of TPL women
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: TPL women
Number of subjects: 126
Study: 25583832

Group type: EXPERIMENTAL
Intervention: dalfampridine-ER 10 mg twice daily
Number of subjects: 269

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 269
Study: 23362895

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with ropivacaine 0.1% (Group 1)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with ropivacaine 0.375% (Group 2)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Epidural anaesthesia with ropivacaine 0.375% for abdominal wall pain and ropivacaine 0.1% for visceral pain (Group 3)
Number of subjects: 75

Group type: COMPARATOR
Intervention: General anaesthesia with target-controlled infusion of propofol and remifentanil
Number of subjects: 75
Study: 21459988

Group type: EXPERIMENTAL
Intervention: Interpersonal psychotherapy
Number of subjects: 70

Group type: COMPARATOR
Intervention: Usual care psychotherapy
Number of subjects: 70
Study: 19114908

Group type: EXPERIMENTAL
Intervention: Tight glycemic control (target glycemia, 80‐110 mg/dL)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Conventional glycemic control (control group, target glycemia, 180‐200 mg/dL)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Fibrinolysis inhibition
Number of subjects: 90
Study: 16716515

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 15562057

Group type: EXPERIMENTAL
Intervention: Propofol-LCT/MCT 1% 2 mg/kg IV
Number of subjects: 200

Group type: COMPARATOR
Intervention: Propofol 1% with IV lidocaine pretreatment
Number of subjects: 200
Study: 11586195

Group type: EXPERIMENTAL
Intervention: Ureteral stents
Number of subjects: 113

Group type: COMPARATOR
Intervention: No ureteral stents
Number of subjects: 113
Study: 9329515

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol 24 micrograms bid for 4 weeks
Number of subjects: 22

Group type: COMPARATOR
Intervention: Inhaled placebo
Number of subjects: 22
Study: 7950723

Group type: EXPERIMENTAL
Intervention: Personal health education
Number of subjects: 688

Group type: COMPARATOR
Intervention: Control (no education)
Number of subjects: 688
Study: 3297528

Group type: EXPERIMENTAL
Intervention: Isoprodian plus rifampicin
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Isoprodian plus pyrazinamide
Number of subjects: 436

Group type: COMPARATOR
Intervention: Standard regimen (isoniazid, streptomycin and pyrazinamide)
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Drug-resistant strains
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Overall relapses
Number of subjects: 436

Group type: EXPERIMENTAL
Intervention: Absconding
Number of subjects: 436
Study: 31376016

Group type: EXPERIMENTAL
Intervention: 810-nm laser irradiation
Number of subjects: 34

Group type: COMPARATOR
Intervention: Sham laser (laser in off mode)
Number of subjects: 34
Study: 30927057

Group type: COMPARATOR
Intervention: CPAP
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: MAD
Number of subjects: 45
Study: 28594800

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 95
Study: 25748562

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 400 or 800 mg pretreatment with intravenous fentanyl 0.5 μg/kg (session 1) or 1.0 μg/kg (session 2)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cannabidiol (CBD) 400 or 800 mg pretreatment
Number of subjects: 0
Study: 23239295

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic surgery (SILS-A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Conventional laparoscopic appendectomy (LAP-A)
Number of subjects: 50
Study: 21528468

Group type: EXPERIMENTAL
Intervention: Modified technique for intramedullary femur nail removal
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional technique for intramedullary femur nail removal
Number of subjects: 9
Study: 18845283

Group type: EXPERIMENTAL
Intervention: Gynecologic treatment plus somatocognitive therapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard gynecologic treatment
Number of subjects: 40
Study: 16494569

Group type: EXPERIMENTAL
Intervention: Unsupplemented children with autism
Number of subjects: 35

Group type: COMPARATOR
Intervention: Unsupplemented control subjects
Number of subjects: 35
Study: 12934203

Group type: EXPERIMENTAL
Intervention: Patellar resurfacing
Number of subjects: 100

Group type: COMPARATOR
Intervention: No patellar resurfacing
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study: 10998313

Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 100
Study: 9148356

Group type: COMPARATOR
Intervention: Balanced anesthesia with isoflurane (expiratory fraction between 0.5% and 0.6%)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) with propofol infusion (12 to 6 mg/kg/h)
Number of subjects: 24
Study: 8416664

Group type: EXPERIMENTAL
Intervention: Vitamin supplement (10 mg pyridoxal, 1.0 mg folic acid, 0.4 mg cyanocobalamin)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Vitamin B-6, B-12, and folate nutritional status
Number of subjects: 44

Group type: COMPARATOR
Intervention: Suboptimal vitamin status
Number of subjects: 44
Study: 3503570

Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31986170

Group type: EXPERIMENTAL
Intervention: NAXOZOL (naproxen 500 mg, esomeprazole strontium tetrahydrate 20 mg) twice per day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib 200 mg daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAXOZOL
Number of subjects: 0

Group type: COMPARATOR
Intervention: Celecoxib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: NAXOZOL and Celecoxib
Number of subjects: 0
Study: 29767350

Group type: EXPERIMENTAL
Intervention: Diet only
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise training
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Diet and resistance exercise training
Number of subjects: 124
Study: 26338825

Group type: EXPERIMENTAL
Intervention: S10 (sequential therapy for 10 days)
Number of subjects: 1300

Group type: COMPARATOR
Intervention: T14 (triple therapy for 14 days)
Number of subjects: 1300

Group type: EXPERIMENTAL
Intervention: S10
Number of subjects: 1300

Group type: COMPARATOR
Intervention: T14
Number of subjects: 1300
Study: 24373984

Group type: EXPERIMENTAL
Intervention: AMP + FACT (n=39)
Number of subjects: 79

Group type: COMPARATOR
Intervention: iCBT (n=40)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group (n=39)
Number of subjects: 79

Group type: COMPARATOR
Intervention: AMP (active condition reported by Carlbring et al.)
Number of subjects: 79
Study: 22932084

Group type: EXPERIMENTAL
Intervention: Gefarnate 300 mg daily for six weeks
Number of subjects: 253

Group type: COMPARATOR
Intervention: Sucralfate 3 g daily for six weeks
Number of subjects: 253
Study: 20219096

Group type: EXPERIMENTAL
Intervention: Nurse led intervention plus education pack
Number of subjects: 121

Group type: COMPARATOR
Intervention: Education pack only
Number of subjects: 121
Study: 16778147

Group type: EXPERIMENTAL
Intervention: Nicotine gum plus motivational interviewing (MI)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Motivational interviewing (MI) and educational materials addressing fruit and vegetable consumption
Number of subjects: 173
Study: 15703500

Group type: EXPERIMENTAL
Intervention: Qi Gong and group discussions
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 95
Study: 12074370

Group type: EXPERIMENTAL
Intervention: Cognitive‐behavior therapy (CBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined CBT+PCT (COMB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pharmacotherapy (PCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Medication placebo (PLA)
Number of subjects: 0
Study: 9788025

Group type: EXPERIMENTAL
Intervention: Iotrolan 320
Number of subjects: 120

Group type: COMPARATOR
Intervention: Iohexol 350
Number of subjects: 120
Study: 8109654

Group type: EXPERIMENTAL
Intervention: 5 mg of trihexyphenidyl twice daily for 4 weeks
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 2669445

Group type: EXPERIMENTAL
Intervention: Sulpiride
Number of subjects: 47

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 47
Study: 775358

Group type: EXPERIMENTAL
Intervention: 1.0 mg LHRH nasal spray per day
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30569507

Group type: EXPERIMENTAL
Intervention: LCR1 and LCR2 tests
Number of subjects: 9892

Group type: COMPARATOR
Intervention: Standard surveillance (imaging with or without AFP)
Number of subjects: 9892
Study: 27712095

Group type: EXPERIMENTAL
Intervention: Self‐Determination Theory (SDT) intervention designed to promote oral health care competence in an autonomy‐supportive way
Number of subjects: 138

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 138
Study: 26700738

Group type: EXPERIMENTAL
Intervention: Epoetin beta (EPO)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Control group (no EPO)
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 227
Study: 25273991

Group type: EXPERIMENTAL
Intervention: CBPT Program
Number of subjects: 260

Group type: COMPARATOR
Intervention: Education Program
Number of subjects: 260
Study: 22428137

Group type: EXPERIMENTAL
Intervention: 6 mg per day oral supplementation and 2 ml (78.9 μM solution) per day topical application of astaxanthin (open-label non-controlled study)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 6 mg of astaxanthin daily supplementation (randomized double-blind placebo controlled study)
Number of subjects: 66
Study: 20134279

Group type: EXPERIMENTAL
Intervention: Tailored, one-on-one educational intervention
Number of subjects: 20
Study: 18030651

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZDs) prescribed
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Benzodiazepines (BZDs) use
Number of subjects: 505

Group type: EXPERIMENTAL
Intervention: Multiple logistic regression analysis
Number of subjects: 505
Study: 15630360

Group type: EXPERIMENTAL
Intervention: Guaifenesin
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: HIV+ group
Number of subjects: 54
Study: 12083347

Group type: EXPERIMENTAL
Intervention: lavender vera (lavendula officinalis)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: sweet orange (citrus aurantium)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: tea tree (malaleuca alternifolia)
Number of subjects: 13

Group type: COMPARATOR
Intervention: no aroma (control)
Number of subjects: 13
Study: 10466845

Group type: EXPERIMENTAL
Intervention: BULIT test with long term clinical treatment strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: BULIT test
Number of subjects: 0
Study: 8830062

Group type: EXPERIMENTAL
Intervention: Nefazodone (200 mg) administered twice daily from the evening of day 2 to the morning of day 9, with triazolam (0.25 mg) on days 8 and 9.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo administered on days 1 and 2, with triazolam (0.25 mg) on days 8 and 9.
Number of subjects: 12
Study: 1512434

Group type: EXPERIMENTAL
Intervention: Cognitive restructuring to promote adaptive beliefs about memory
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Memory skills training
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Combined cognitive restructuring and memory skills training
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Practice on memory tasks
Number of subjects: 5

Group type: COMPARATOR
Intervention: No-contact control group
Number of subjects: 5
Study: 6235779

Group type: EXPERIMENTAL
Intervention: Toxicodendron antigen patch test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Delayed (96-hour) patch test reading
Number of subjects: 0
Study: 30284455

Group type: EXPERIMENTAL
Intervention: Composite sinus stent implantation for 14 to 28 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Telfa tampon placement for 2 to 3 days
Number of subjects: 30
Study: 29282354

Group type: EXPERIMENTAL
Intervention: Plastic bag intervention
Number of subjects: 108

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 108
Study: 26799942

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids (6 grams per day for 3 months)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study: 28526087

Group type: EXPERIMENTAL
Intervention: New Opportunities (DNK)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Care as Usual (CAU)
Number of subjects: 300
Study: 23400604

Group type: EXPERIMENTAL
Intervention: Folic acid
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Iron/folic acid (60 mg iron)
Number of subjects: 850

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (30 mg iron)
Number of subjects: 850

Group type: COMPARATOR
Intervention: Control group (prenatal-non-IDA)
Number of subjects: 850
Study: 20878213

Group type: EXPERIMENTAL
Intervention: Workplace fitness program (3 sessions per week for 8 months, 15 minutes per session, focusing on stretching exercises)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study: 19950567

Group type: EXPERIMENTAL
Intervention: Midodrine hydrochloride
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Cresol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Health education
Number of subjects: 48
Study: 17171354

Group type: EXPERIMENTAL
Intervention: Stapled hemorrhoidopexy (SH)
Number of subjects: 596

Group type: COMPARATOR
Intervention: Ferguson hemorrhoidectomy (FH)
Number of subjects: 596
Study: 15238825

Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 40
Study: 11220045

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 18

Group type: COMPARATOR
Intervention: Controls (no medication)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of pill users with controls
Number of subjects: 18

Group type: COMPARATOR
Intervention: Normal cyclic variations in healthy young females
Number of subjects: 18
Study: 9627608

Group type: EXPERIMENTAL
Intervention: 2% lidocaine with epinephrine iontophoresis
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 42
Study: 7604686

Group type: EXPERIMENTAL
Intervention: Patients with pudendal nerve terminal motor latencies > 2.0 milliseconds
Number of subjects: 113

Group type: COMPARATOR
Intervention: Patients and controls (3 months post partum)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Incontinent patients and continent patients
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control women
Number of subjects: 113
Study: 2194899

Group type: EXPERIMENTAL
Intervention: Heat probe coagulation (30 patients)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Observation alone (31 patients)
Number of subjects: 61
Study: 372565

Group type: EXPERIMENTAL
Intervention: Intraoperative intercostal nerve block with bupivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 30
Study: 30926995

Group type: EXPERIMENTAL
Intervention: Debiasing intervention (visual aid and explanatory text)
Number of subjects: 311

Group type: COMPARATOR
Intervention: Control stimulus
Number of subjects: 311

Group type: COMPARATOR
Intervention: Post-test only group
Number of subjects: 311
Study: 30777495

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 0 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 20 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 40 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 60 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 80 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 100 min
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Thawed ovarian tissue at 120 min
Number of subjects: 11
Study: 28860419

Group type: EXPERIMENTAL
Intervention: Quadriceps cooling (QC)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Hamstring cooling (HC)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no cooling)
Number of subjects: 30
Study: 26193339

Group type: EXPERIMENTAL
Intervention: High DNA index (>1.4)
Number of subjects: 143

Group type: COMPARATOR
Intervention: Low DNA index (G1/2 tumor grading)
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: DNA index and tumor grading
Number of subjects: 143

Group type: EXPERIMENTAL
Intervention: Prognostic subgroups based on DNA index and tumor grading
Number of subjects: 143
Study: 23263865

Group type: EXPERIMENTAL
Intervention: Belimumab
Number of subjects: 1684

Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil + Belimumab
Number of subjects: 1684

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1684
Study: 20855467

Group type: EXPERIMENTAL
Intervention: DHA‐paclitaxel at a starting dose of 900 mg/m(2) IV on day 1 every 3 weeks
Number of subjects: 393

Group type: COMPARATOR
Intervention: Dacarbazine at a starting dose of 1000 mg/m(2) IV on day 1 every 3 weeks
Number of subjects: 393

Group type: EXPERIMENTAL
Intervention: DHA‐paclitaxel
Number of subjects: 393

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 393
Study: 19576297

Group type: EXPERIMENTAL
Intervention: Rectal enemas (3 enemas/week, reduced by 1 enema/week every 3 months)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral laxatives (control group)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Overall success rate
Number of subjects: 100
Study: 17101006

Group type: EXPERIMENTAL
Intervention: Hair dye A (24 hr exposure)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Hair dye B (24 hr exposure)
Number of subjects: 3

Group type: COMPARATOR
Intervention: 1% PPD/petrolatum (48 hr exposure)
Number of subjects: 3
Study: 14985212

Group type: EXPERIMENTAL
Intervention: Chickpea-based meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wheat-based meal
Number of subjects: 20

Group type: COMPARATOR
Intervention: White bread meal
Number of subjects: 20
Study: 11710999

Group type: EXPERIMENTAL
Intervention: 5 MIU IFN-alpha s.c. daily for 32 consecutive days (IFN-alphaT group)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Not applicable (IFN-alphaNT group)
Number of subjects: 27
Study: 9135948

Group type: EXPERIMENTAL
Intervention: sulodexide (100 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 7957000

Group type: EXPERIMENTAL
Intervention: Codfish (1 g fat, 23 g protein per 100 g)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Walnuts (64 g fat, 7 g protein, 15 g starch per 100 g)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Bananas (22 g starch, 1 g protein per 100 g)
Number of subjects: 7
Study: 2193498

Group type: EXPERIMENTAL
Intervention: Indecainide
Number of subjects: 32

Group type: COMPARATOR
Intervention: Procainamide
Number of subjects: 32
Study: 380579

Group type: EXPERIMENTAL
Intervention: Viloxazine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amitriptyline
Number of subjects: 0
Study: 31144466

Group type: EXPERIMENTAL
Intervention: Test in Mandarin developed from the Claim Evaluation Tools database, consisting of 21 MCQs after deletion of 3 with suboptimal fit.
Number of subjects: 389
Study: 29143634

Group type: EXPERIMENTAL
Intervention: Single oral dose of 3 μg/kg of moxidectin
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Three consecutive monthly doses of 3 μg/kg of moxidectin
Number of subjects: 9
Study: 25888086

Group type: EXPERIMENTAL
Intervention: Organ Care System
Number of subjects: 130

Group type: COMPARATOR
Intervention: Standard cold storage
Number of subjects: 130
Study: 23475780

Group type: EXPERIMENTAL
Intervention: Net fluid loss in the first 24 hours
Number of subjects: 475

Group type: EXPERIMENTAL
Intervention: Baseline right atrial pressure (RAP) and decrease in RAP
Number of subjects: 475
Study: 21447866

Group type: EXPERIMENTAL
Intervention: Undetectable viraemia at week 24
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Detectable viraemia <15 IU/ml at week 24
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Detectable viraemia 15-<50 IU/ml at week 24
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Negative predictive value (NPV) for SVR using TaqMan cutoffs
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Agreement between Amplicor and TaqMan assays
Number of subjects: 871
Study: 19905037

Group type: EXPERIMENTAL
Intervention: HAART programme
Number of subjects: 1045
Study: 17112296

Group type: EXPERIMENTAL
Intervention: Regadenoson (CVT‐3146) at doses ranging from 0.1 to 30.0 micro g/kg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Regadenoson (CVT‐3146)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 16212202

Group type: EXPERIMENTAL
Intervention: Ceftriaxone (single dose)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ampicillin/cloxacillin (3 doses)
Number of subjects: 200
Study: 11327628

Group type: EXPERIMENTAL
Intervention: Nifedipine (20 mg, p.o.)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Captopril (50 mg, p.o.)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Healthy controls (normotensive subjects)
Number of subjects: 64
Study: 9394872

Group type: EXPERIMENTAL
Intervention: Divalproex (DIVAL)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Lithium (LI)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 176
Study: 7906406

Group type: EXPERIMENTAL
Intervention: Halothane-diethyl ether azeotrope anesthesia (HE)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Halothane/nitrous oxide anesthesia
Number of subjects: 20
Study: 3821177

Group type: EXPERIMENTAL
Intervention: Aspirin (975 mg three times daily)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Aspirin and ethanol (maximal doses for 3 days)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Ethanol (300 ml of 5% or 30 ml of 50% three times nightly)
Number of subjects: 68
Study: 28005616

Group type: EXPERIMENTAL
Intervention: TDR
Number of subjects: 229

Group type: COMPARATOR
Intervention: Fusion
Number of subjects: 229